The effect of obesity on treatment efficacy in children with nocturnal enuresis and voiding dysfunction

Ahmet Guven1, Karla Giramonti, Barry A Kogan

  • 1Division of Urology, Section of Pediatric Urology, Albany Medical College, Albany, New York 12208, USA.

The Journal of Urology
|August 21, 2007
PubMed

Insights

Obesity in children with voiding issues, like nocturnal enuresis, is linked to poorer treatment outcomes. Higher body mass index correlates with reduced treatment effectiveness and lower diary completion rates.

Area of Science:

  • Pediatric Urology
  • Public Health
  • Pediatric Endocrinology

Background:

  • Obesity is a significant public health issue in the U.S.
  • Previous research indicates a high prevalence of obesity in children with dysfunctional voiding and nocturnal enuresis.

Purpose of the Study:

  • To investigate the relationship between body mass index (BMI) and treatment efficacy in pediatric patients with voiding dysfunction.
  • To determine if obesity impacts treatment outcomes for nocturnal enuresis and dysfunctional voiding.

Main Methods:

  • Retrospective review of 250 pediatric patients diagnosed with nocturnal enuresis or dysfunctional voiding (2004-2005).
  • Evaluation of bladder/bowel symptoms, urinary diary data, and BMI percentile.
  • Correlation analysis between BMI percentile and treatment response.

Main Results:

  • 38% of patients had nocturnal enuresis, 62% had dysfunctional voiding.
  • Half of the patients had a BMI at or above the 85th percentile.
  • Higher BMI correlated with reduced treatment response rates (65% normal BMI vs. 35% high BMI for voiding dysfunction).
  • Patients with normal BMI had fewer nocturnal accidents and higher urinary diary completion rates.

Conclusions:

  • Obesity is associated with diminished treatment efficacy in children with nocturnal enuresis and dysfunctional voiding.
  • Higher BMI negatively impacts treatment success and patient adherence to monitoring tools like urinary diaries.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Diabetes Insipidus II: Pathophysiology01:22

Diabetes Insipidus II: Pathophysiology

Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention01:27

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...